A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer

Trial Title: A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer

NCT ID: NCT05839600

Condition: Solid Tumors

Study type: Interventional

Study phase: Phase 1

Overall status: Suspended

Study design:

Allocation: N/A

Intervention model: Sequential Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: BI 1821736
Description: Solution for infusion
Arm group label: BI 1821736: Dose escalation cohort

Summary: This study is open to adults with advanced solid tumours. People with solid tumours for whom previous treatment was not successful or no treatment exists can take part. The purpose of this study is to find the highest dose of a medicine called BI 1821736 that people with advanced solid tumours can tolerate. BI 1821736 is a type of immunotherapy. It is a special virus that kills cancer cells and helps the immune system fight cancer. In this study, BI 1821736 is given to humans for the first time. Participants receive BI 1821736 as an infusion into a vein about every 3 weeks for up to 3 months. Study doctors regularly check the participants' health and monitor the tumours. The doctors also take note of any unwanted effects that could have been caused by BI 1821736.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Histologically confirmed diagnosis of malignant tumor. - Advanced, unresectable and/or metastatic or relapsed/refractory solid tumors. - Has failed conventional treatment or for whom no therapy of proven efficacy exists or who is not eligible for established treatment options. Patient must have exhausted available treatment options known to prolong survival for their disease. - Has at least one tumoral lesion which is amenable to biopsy. - Signed and dated, written informed consent form (ICF) in accordance with ICH-GCP and local legislation obtained prior to any trial-specific procedures, sampling, or analyses that are not part of normal standard of practice care. - Eastern Cooperative Oncology Group score of 0 or 1. - Adequate organ function or bone marrow reserve defined as demonstrated at screening by the following laboratory values: - Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (≥ 1.5 x 10^3/μL)(≥ 1500/mm^3); haemoglobin ≥ 90 g/L (≥ 9.0 g/dL)(≥ 5.6 mmol/L); platelets ≥ 100 x 10^9/L (≥ 100 x 10^3/μL)(≥ 100 x 10^3/mm^3) without the use of haematopoietic growth factors within 4 weeks of start of trial medication. - Creatinine ≤ 1.5 times the upper limit of normal (ULN). - Total bilirubin ≤ 1.5 times the ULN, except for patients with Gilbert's syndrome: total bilirubin ≤ 3 times ULN or direct bilirubin ≤ 1.5 times ULN. - Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 times ULN if no demonstrable liver metastases, or otherwise ≤ 5 x ULN if transaminase elevation is attributable to liver metastases. - Partial thromboplastin (PT) / activated partial thromboplastin time (aPTT) <1.5 times ULN unless on a stable dose of an anticoagulant. - All toxicities related to previous anti-cancer therapies have resolved to ≤ Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 prior to trial treatment administration (except for alopecia and peripheral neuropathy which must be ≤ CTCAE Grade 2 and amenorrhea/menstrual disorders which can be any grade). - Further inclusion criteria apply Exclusion Criteria: - Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to start of study treatment. - Previous treatment with Vesicular Stomatitis Virus (VSV)-based agents. - Patients with brain metastases unless they have completed brain radiotherapy and are asymptomatic. - Radiotherapy within 4 weeks prior to the start of study treatment, except in case of a brief course of palliative radiotherapy (e.g. for analgesic purpose or for lytic lesions at risk of fracture) which can then be completed within two weeks prior to start of study treatment. Note: No radiation must have been given to any lesions planned to be biopsied within 6 months of start of treatment. - Prior (within 3 weeks of first dose) or concomitant use of systemic corticosteroids (>10 mg daily prednisone or equivalent). - Prior (within 3 weeks of first dose or less than 5 half-lives) or concomitant use of a medication or a condition considered a high risk for complications from biopsy as per the Investigator's judgement. - Prior (within 3 weeks of first dose or less than 5 half-lives) or concomitant use of interferon, immunotherapy agents, or tamoxifen. - Active infection requiring systemic therapy (antibacterial, antiviral, antiparasitic or antifungal therapy) at the start of treatment in the trial. - Further exclusion criteria apply

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Yale Cancer Center

Address:
City: New Haven
Zip: 06511
Country: United States

Facility:
Name: The University of Texas MD Anderson Cancer Center

Address:
City: Houston
Zip: 77030
Country: United States

Facility:
Name: NEXT Oncology

Address:
City: San Antonio
Zip: 78229
Country: United States

Facility:
Name: Princess Margaret Cancer Centre

Address:
City: Toronto
Zip: M5G 2M9
Country: Canada

Facility:
Name: Hospital Quiron. I.C.U.

Address:
City: Barcelona
Zip: 08023
Country: Spain

Facility:
Name: Hospital Clínic de Barcelona

Address:
City: Barcelona
Zip: 08036
Country: Spain

Facility:
Name: Hospital Universitario 12 de Octubre

Address:
City: Madrid
Zip: 28041
Country: Spain

Facility:
Name: Instituto Valenciano de Oncología

Address:
City: Valencia
Zip: 46009
Country: Spain

Facility:
Name: Karolinska Universitetssjukhuset Stockholm

Address:
City: Stockholm
Zip: 17177
Country: Sweden

Start date: May 25, 2023

Completion date: January 26, 2027

Lead sponsor:
Agency: Boehringer Ingelheim
Agency class: Industry

Source: Boehringer Ingelheim

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05839600
http://www.mystudywindow.com